Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data

Figure 3 Comparisons of area under the receiver operating characteristic curve (AUROC) for percent genome change, α-fetoprotein, and tumor size in early-stage hepatocellular carcinoma, and Kaplan-Meier plot for 10-yr disease-free survival in patients with hepatocellular carcinoma with or without ≥ 60% genome change. A: AUROC analysis of AFP (dotted line, 0.598), tumor size (dashed line, 0.633), and percent genome change (solid line, 0.657) shows predictive ability for early-stage HCC recurrence. Cutoffs for AFP, tumor size, and percent genome change are 5.2 ng/mL, 4.25 cm, and 30%, respectively (Supplementary Table 3). B: The Kaplan-Meier plot for 10-yr disease-free survival in patients with HCC with ≥ 60% (dashed line) or < 60% (solid line) genome change as determined from Affymetrix OncoScan CNA data. AFP: α-fetoprotein; HCC: Hepatocellular carcinoma.